A proof-of-concept trial evaluating the effects of Relief Therapeutics’ antimicrobial wound spray RLF-TD011 — formerly known as APR-TD011 — in people with epidermolysis bullosa (EB) has enrolled its first three patients, the company announced. RLF-TD011 is a highly pure form of hypochlorous acid, a chemical with broad-spectrum…
From sharing images and information on social media, to holding fundraisers to spread the word about epidermolysis bullosa (EB), supporters are set to mark National Epidermolysis Bullosa Awareness Week Oct. 25–31. “National Epidermolysis Bullosa Awareness Week … is a time to increase awareness of EB, to promote the need for a…
Squamous cell carcinoma (SCC), a type of skin cancer well known in people with recessive dystrophic epidermolysis bullosa (RDEB), also affects patients with other EB types, according to data from the Dutch EB registry. “The tumours might be discovered only when they are already large because of their indistinct…
Krystal Biotech is seeking U.S. Food and Drug Administration (FDA) approval of Vyjuvek (previously called B-VEC), its topical gene therapy for people with dystrophic epidermolysis bullosa (DEB). The request was made in the form of a biologics license application or BLA — a type of marketing approval —…
Tetra Bio-Pharma’s investigational cannabinoid cream PPP004 (THC-CBD) has been granted orphan drug status by the European Medicines Agency (EMA) to treat epidermolysis bullosa. This follows the orphan drug designation granted to PPP004 by the U.S. Food and Drug Administration (FDA) for the same purpose in April 2020.
Vitamin D supplements are necessary to increase and normalize the vitamin’s levels in the blood of children with recessive dystrophic epidermolysis bullosa (RDEB), according to a single center study in the U.K. Also, the dose should increase with age and can be three times higher than that recommended for…
At-home inhalation of nitrous oxide, a colorless gas commonly used for sedation, may help reduce pain during wound dressings in patients with severe recessive dystrophic epidermolysis bullosa (DEB), a case report shows. For a 28-year-old man in Italy with spontaneous and frequent blisters due to severe DEB, “the beneficial…
Pain, but not wound size, significantly affects a person’s perception of disease severity with dominant dystrophic epidermolysis bullosa (DEB), a study reports. Chronic open wounds, difficulty swallowing or walking, and anal narrowing also plays into patients’ perceptions of their disease’s severity. The study, “Patient-reported outcomes and…
The U.S. Food and Drug Administration (FDA) has extended by three months its review of Amryt Pharma’s application seeking approval of Filsuvez (Oleogel-S10), a topical gel to treat skin wounds in people epidermolysis bullosa (EB). A regulatory decision is now expected on Feb. 28 — it previously was set…
A Phase 2 trial into the safety and early efficacy of INM-755, a cannabinol cream for people with epidermolysis bullosa (EB), will soon begin enrolling patients across Europe and Israel. “The start of this Phase 2 clinical trial represents a very important step forward to test the efficacy of INM-755…
HMP Global’s Symposium on Advanced Wound Care (SAWC) Fall has established partnerships with the Wound Healing Foundation and debra of America to boost their research and improve care of patients with chronic wounds, such as those with epidermolysis bullosa (EB). The SAWC Fall is scheduled to…
Malnutrition, both moderate and severe, is fairly common among children with epidermolysis bullosa (EB) living in India, a study suggests. A child’s degree of malnutrition also correlated with disease severity, its researchers reported. A personalized diet followed for six months significantly improved patients’ nutritional status, particularly among children with dystrophic…
Get regular updates to your inbox.